The QualityStocks Daily Tuesday, April 11th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(LUCY) $4.4000 +201.37%

Schaeffer's(WW) $6.5500 +58.98%

QualityStocks(NCMI) $0.2061 +54.96%

The QualityStocks Daily Stock List

National CineMedia (NCMI)

InvestorPlace, Kiplinger Today, MarketBeat, StreetInsider, Schaeffer's, BUYINS.NET, Daily Trade Alert, Trades Of The Day,, MarketClub Analysis, StockMarketWatch, Dividend Opportunities, SmarTrend Newsletters, Street Insider, StreetAuthority Daily, The Street, The Street Report, Wealth Insider Alert, WealthMakers, The Online Investor, TopStockAnalysts, Greenbackers, Dynamic Wealth Report, Trading Concepts, Daily Market Beat and QualityStocks reported earlier on National CineMedia (NCMI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

National CineMedia, Inc. (NASDAQ: NCMI) (FRA: XWM) is a holding firm that operates a cinema advertising network in North America via its National CineMedia LLC subsidiary.

The firm has its headquarters in Centennial, Colorado and was incorporated in 2006, on October 5th. It serves consumers in the U.S. and is focused on providing event, digital programing, business meetings and advertising services. It also provides its services to 3rd party theater circuits under long-term network affiliate agreements.

The enterprise operates and owns Fathom Events, a digital in-theater network which distributes content for advertising promotions. It also sells advertising to local, regional and national businesses in a cinema advertising and entertainment pre-show known as Noovie, which is seen on movie screens. In addition to this, it sells mobile and online advertising via its Cinema Accelerator digital product dubbed Noovie Audience Acccelerator, to reach entertainment audiences beyond theater. Furthermore, it uses Noovie digital properties like Noovie Arcade, Name That Movie, Noovie Trivia, Noovie Shuffle and to reach other audiences. The enterprise is also involved in the sale of advertising on its Lobby Entertainment Network, which comprises of strategically-places screens that can be found in lobbies in movie theaters, as well as other promotions and forms of advertising in theater lobbies.

The company has entered into multiple affiliate agreements with various exhibitors, which will allow its Noovie pre-show program to be viewed on more than 300 screens across almost 40 theaters. This move will also help the company’s network grow, which may encourage more investments into the firm and boost its growth.

National CineMedia (NCMI), closed Tuesday's trading session at $0.2061, up 54.9624%, on 113,253,400 volume with 00 trades. The average volume for the last 3 months is 182,885 and the stock's 52-week low/high is $0.1008 /$2.57 .

Avalo Therapeutics (AVTX)

QualityStocks and MarketBeat reported earlier on Avalo Therapeutics (AVTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avalo Therapeutics Inc. (NASDAQ: AVTX) (FRA: C6K0) is a clinical stage medicine firm that is focused on discovering, developing and commercializing therapeutics for patients with unmet clinical needs in rare genetic, immune-oncology and immunology illnesses.

The firm has its headquarters in Rockville, Maryland and was incorporated in 2011, on January 31st by Solomon H. Snyder, Barbara S. Slusher, Isaac Blech and Blake M. Paterson. Prior to its name change in August 2021, the firm was known as Cerecor Inc. It operates as part of the scientific research and development services industry and serves consumers around the world.

The company uses a precision medicine approach to develop and commercialize highly targeted therapeutics. It operates a bioassay facility in Germantown.

The enterprise’s product pipeline is made up of an anti-light mAb dubbed AVTX-002, which targets immune-inflammatory ailments like moderate-to-severe inflammatory bowel disease and acute respiratory distress syndrome. It also offers an anti-IL-18 mAb, which targets immune-inflammatory and immune-oncology illnesses like Still’s disease and multiple myeloma. Still’s disease is a disorder that’s characterized by arthritis, a rash, high spiking fevers and inflammation. In addition to this, the enterprise also develops AVTX-801, AVTX-802 and AVTX-803, which are therapeutic monosaccharide therapy doses indicated for congenital disorders of glycosylation; and a dual mTORc1/c2 inhibitor dubbed AVTX-006, which targets lymphatic malformations.

The firm is focused on addressing the significant unmet medical need for patients and advancing its programs, having recently expanded its AVTX-002 program. Meeting these needs will not only extend the firm’s consumer reach but also encourage more investments into the firm, which will be good for its growth.

Avalo Therapeutics (AVTX), closed Tuesday's trading session at $3.1, up 30.2521%, on 183,630 volume with 00 trades. The average volume for the last 3 months is 472,298 and the stock's 52-week low/high is $1.41 /$8.40 .

Cardiol Therapeutics (CRDL)

MarketBeat and QualityStocks reported earlier on Cardiol Therapeutics (CRDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSE: CRDL) (FRA: CT9) is a clinical-stage biotechnology firm that is engaged in the research and development of anti-inflammatory cannabidiol therapies for treating cardiovascular ailments.

The firm has its headquarters in Oakville, Canada and was incorporated in 2017, on January 19th by Anthony Bolton, Eldon Smith and David Elsley. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry.

The company uses its expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in various medical markets. It also develops nanotechnology that boosts pharmacokinetics, facilitates drug accumulation in a failing heart and allows for the distribution of water insoluble medications in an individual’s blood circulation.

The enterprise’s pipeline is made up of a subcutaneous formulation of cannabidiol which helps achieve higher bioavailability for the treatment of chronic heart failure; and a cannabidiol oral formulation dubbed CardiolRx, indicated for the treatment of coronavirus patients in hospitalization who have a history of risk factors for cardiovascular disease. The high concentration formulation recently concluded phase 1 clinical trials testing its effectiveness in treating acute myocarditis. The enterprise also has an immunotherapeutics program that is focused on developing a cancer immunotherapeutic in combination with cannabinoids, for the treatment of glioblastoma multiforme.

The firm’s CardiolRx formulation; which has been developed for hospitalized coronavirus patients with risk factors or a history of cardiovascular disease, received IND approval from the FDA. This move builds confidence in the formulation and brings it one step closer to new drug application and commercialization, which may bring in move investments into the firm and boost its growth.

Cardiol Therapeutics (CRDL), closed Tuesday's trading session at $0.6363, up 24.0109%, on 472,298 volume with 00 trades. The average volume for the last 3 months is 55,160 and the stock's 52-week low/high is $0.45 /$2.08 .

Eledon Pharmaceuticals (ELDN)

MarketBeat and QualityStocks reported earlier on Eledon Pharmaceuticals (ELDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) (FRA: 2TK) is a clinical stage biopharmaceutical firm that is engaged in the development of medications for individuals living with amyotrophic lateral sclerosis and autoimmune ailments.

The firm has its headquarters in Irvine, California and was incorporated in 2004, on March 26th. Prior to its name change in January 2021, the firm was known as Novus Therapeutics Inc. The firm serves consumers in the United States.

The company uses its expertise to target the CD40L pathway to develop new treatments for individuals with neurodegenerative and autoimmune ailments, as well as for individuals undergoing organ or cellular transplantation. The CD40L/CD40 pathway is known for its important role in immune regulation, which makes it a candidate for therapeutic intervention in neuro-inflammation, autoimmune ailments and transplant tolerance.

The enterprise’s product pipeline comprises of a humanized monoclonal antibody dubbed AT-1501, which targets CD40 ligand that’s a molecule expressed on the surface of T cells in the human immune system. The formulation is built upon a historical understanding of the CD40/CD40L pathway. It is currently in phase 2 clinical trials evaluating its effectiveness in treating amyotrophic lateral sclerosis. In addition to this, the formulation is also undergoing phase 2 clinical trials in islet cell transplantation, for treating type 1 diabetes.

The company recently entered into a collaborative research agreement with CareDx Inc. which will entail evaluating the effectiveness of the company’s AT-1501 formulation using CareDx’s technology. This agreement moves the company one step closer to getting its AT-1501 formulation to approval and will also bring in more opportunities for the company, which will be good for its growth.

Eledon Pharmaceuticals (ELDN), closed Tuesday's trading session at $2.47, up 22.2772%, on 55,276 volume with 00 trades. The average volume for the last 3 months is 1,225 and the stock's 52-week low/high is $1.68 /$3.95 .

Juventus Football Club (JVTSF)

MarketBeat reported earlier on Juventus Football Club (JVTSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Juventus Football Club S.p.A. (OTC: JVTSF) (BIT: JUVE) (FRA: JUVE) (BMV: JUVEN) is a company that is focused on operating a professional football club.

The firm has its headquarters in Turin, Italy and was incorporated in 1897, on November 1st. It operates as part of the entertainment industry, under the communication services sector. The firm mainly serves consumers in Italy.

The company operates as a subsidiary of EXOR N.V. It belongs to the Italian Serie A division. The company is active mainly locally. It generates revenue from the sale of tickets, sponsorship activities, sale of advertising space, as well as licensing of television and media rights.

The enterprise’s core business is participation in national and international competitions and the organization of matches while exploiting sports events, the Juventus brand and the team image, including also the licensing of television and media rights, sponsorship, selling of advertising space, licensing and merchandising. It also markets additional services to fans and manages players' registration rights. The enterprise owns its stadium, which was inaugurated on 8 September 2011 and was named the Allianz Stadium from the 2017/18 season. In addition, it has its own modern sports center located in Vinovo, which opened in July 2006 and was designed exclusively for Juventus’ Youth and Women teams. In 2017, it transferred its registered offices to the new complex owned by the J Village Property Fund, which is situated in the vicinity of the stadium.

The firm remains committed to better meeting consumer demand and generating value for its shareholders, which will be good for its growth.

Juventus Football Club (JVTSF), closed Tuesday's trading session at $0.335, up -7.7897%, on 1,225 volume with 00 trades. The average volume for the last 3 months is 33,698 and the stock's 52-week low/high is $0.26 /$0.4466 .

MariaDB (MRDB)

We reported earlier on MariaDB (MRDB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MariaDB Plc (NYSE: MRDB) is a cloud database firm that is engaged in the provision of open source database and database as a service (DBaaS) solutions to support scalability, mission-critical deployments, configuring databases for production environments, and automating failover.

The firm has its headquarters in Redwood City, California and was incorporated in 2017, on June 19th. Prior to its name change, the firm was known as Mangomill Plc. It operates as part of the software-infrastructure industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in the U.S. and Ireland.

The enterprise offers MariaDB Community Server, an open-source relational database; MariaDB Enterprise Server, a production-grade open-source database which delivers performance, data security, replication, clustering, and availability; MariaDB Xpand, a distributed SQL database, which combines the scalability of a NoSQL database with the robustness of a SQL database; SkySQL, a fully-managed cloud database service enabling the user to deploy and manage MariaDB Enterprise Server, Xpand distributed SQL, ColumnStore, and Serverless Analytics powered by Apache Spark SQL as database services; and MariaDB ColumnStore, an analytics and data warehousing solution, extends MariaDB Enterprise Server with distributed, columnar storage and a massively parallel processing shared nothing architecture, transforming it into a standalone or distributed data warehouse for ad hoc SQL queries and advanced analytics without the need to create indexes. It also provides technical support, consulting, and training services.

The company recently showcased its new SkySQL cloud database at the AWS Global Summit, a move that’ll help extend its reach while also bringing in additional revenues.

MariaDB (MRDB), closed Tuesday's trading session at $1.24, up -4.6154%, on 33,698 volume with 00 trades. The average volume for the last 3 months is 40,001 and the stock's 52-week low/high is $3.20 /$11.55 .

Aerwins Technology (AWIN)

We reported earlier on Aerwins Technology (AWIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aerwins Technology Inc. (NASDAQ: AWIN) is a company focused on the development and manufacture of drones and other technology in the air infrastructure and air mobility space.

The firm has its headquarters in Tokyo, Japan and was incorporated in 2017. Prior to its name change, the firm was known as Pono Capital Corp. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm serves consumers around the globe.

The company mainly operates through its wholly owned subsidiary, Aerwins Inc. It is focused on enabling proper planning, monitoring, and management of aircraft condition while also ensuring safety of the surrounding environments and operators, which are the principles of automatic operation of UAVs.

The enterprise’s air mobility platform, Centralized Operating System, has been designed to help manage Open Sky (C.O.S.M.O.S.). It has also developed the XTURISMO Limited Edition Hoverbike. C.O.S.M.O.S. is a drone monitoring and management platform service. C.O.S.M.O.S. is an unmanned aerial vehicle (UAV), including drones and air mobility platform that enables proper planning, monitoring and management of aircraft condition, and ensures safety of the surrounding environments and operators. XTURISMO Limited Edition Hoverbike is a luxury air cruiser.

The company recently partnered with Outsourcing Inc. to develop and produce new air mobility products in the Middle East. This move will advance its manufacturing and production capabilities and open it up to new growth and investment opportunities while also bringing in additional revenues into the company.

Aerwins Technology (AWIN), closed Tuesday's trading session at $0.911, up 1.2222%, on 40,001 volume with 00 trades. The average volume for the last 3 months is 420 and the stock's 52-week low/high is $0.78 /$18.00 .

Ezagoo (EZOO)

We reported earlier on Ezagoo (EZOO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ezagoo Limited (OTC: EZOO) is a company mainly engaged in providing digital advertising services to consumers.

The firm has its headquarters in Beijing, China and was incorporated in 2018, on May 9th. It is also known as Hunan Ezagoo Zhicheng Internet Technology Ltd. The company operates as part of the advertising agencies industry, under the communication services sector. The firm mainly serves consumers in the People’s Republic of China.

The company’s primary business activity is to display advertisements for its clients on television screens mounted on public buses that move throughout Changsha City. It conducts its businesses mainly in the domestic market.

The enterprise operates within the Chinese digital advertising network through advertisements displayed on flat-panel audiovisual television displays. It offers display advertisement services on TV screens mounted on public buses and the mobile application named Xindian that operates over the internet. The enterprise focuses on telecommunication, e-commerce, and electronics products for sales.

The firm is focused on growing its business rapidly, given its status as an emerging growth company. It relies heavily on information technology, or IT, systems to manage critical functions such as advertising campaign management and operations, data storage and retrieval, revenue recognition, budgeting, forecasting, financial reporting and other administrative functions. To manage its growth effectively, the firm is committed to improving and expanding its infrastructure, including their IT, financial and administrative systems and controls. This will help create value for its shareholders while also opening it up to new investment opportunities.

Ezagoo (EZOO), closed Tuesday's trading session at $1, up -2.9126%, on 420 volume with 00 trades. The average volume for the last 3 months is 7 and the stock's 52-week low/high is $0.0341 /$1.30 .

Real Matters (RLLMF)

StreetInsider and MarketBeat reported earlier on Real Matters (RLLMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Real Matters Inc. (OTC: RLLMF) (TSE: REAL) (FRA: R3E) is a company engaged in the provision of technology and network management solutions to mortgage lending and insurance industries.

The firm has its headquarters in Markham, Canada and was incorporated in 2004 by Michael A. Johnston. Prior to its name change in July 2010, the firm was known as Solidifi Inc. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in Canada and the United States.

The company operates through the following segments: United States Appraisal, United States Title, and Canada. The United States Appraisal segment offers residential mortgage appraisals for purchase, refinance, home equity, and default transactions through its Solidifi brand. The United States Title segment serves the title market by providing various title services for refinance, purchase, short sale, and real estate owned transactions to financial institutions through its Solidifi brand. The Canada segment includes residential mortgage appraisals for purchase, refinance, and home equity transactions provided through its Solidifi brand. The company generates maximum revenue from the U.S. Appraisal segment.

The enterprise also offers insurance inspection services to property and casualty insurers across Canada through its iv3 brand. It serves real estate appraisers, lenders, mortgage insurers, and originators in the North American financial services industry.

The firm, which is set to announce its latest financial results, remains focused on increasing its share of the market and increasing its revenues. This will positively influence shareholder value as well as boost the firm’s overall growth.

Real Matters (RLLMF), closed Tuesday's trading session at $3.4, up 0%, on volume with 00 trades. The average volume for the last 3 months is 1.98M and the stock's 52-week low/high is $3.02 /$4.74 .

Corteva Agriscience (CTVA)

MarketBeat, MarketClub Analysis, InvestorPlace, Trades Of The Day, Kiplinger Today, Daily Trade Alert, The Street, Schaeffer's, Zacks, Stock Up Featured, The Online Investor, Top Pros' Top Picks, TipRanks, TradersPro, Trading Tips, Investopedia, InsiderTrades, DividendStocks and StreetInsider reported earlier on Corteva Agriscience (CTVA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ROTH MKM (“Roth”),, a relationship-driven investment bank focused on serving growth companies and their investors, is pleased to announce that their agribusiness investment banking group has advised on three sellside transactions in the past nine months. The transactions included business models in the areas of cover crops, gene editing, biologicals, bio stimulants, and alternative fertilizers, and demonstrate the group's expertise in designing and executing M&A processes to achieve the best outcomes for its clients in a wide array of agriculture related sectors.

ROTH MKM's Agribusiness Investment Banking Group served as the sellside advisor on the following transactions:

  • Exclusive advisor to Symborg, a company based in Murcia, Spain, with cutting edge microbiological technology, acquired by Corteva Agriscience (NYSE: CTVA)
  • Advisor to Marrone Bio Innovations (NASDAQ: MBII), a leading biological crop inputs platform, based in Davis, CA, acquired by Bioceres Crop Solutions (NASDAQ: BIOX)
  • Exclusive advisor to CoverCress Inc., an innovative start-up based in St. Louis, MO, developing and commercializing a new rotational winter oilseed crop that generates a low carbon intensity oil feedstock for renewable fuel production, in the execution of an exit transaction involving three strategic interests, Bayer (OTC: BAYRY), Bunge (NYSE: BG) and Chevron (NYSE: CVX).

“We appreciate our clients' confidence in us as we strive to achieve the best outcomes for their shareholders," said Alex Stoyanov, Managing Director, and Head of M&A for ROTH MKM.

"ROTH MKM has built a dedicated agribusiness effort with investment banking and research resources that exclusively work with entities whose business models are influenced by agriculture and are the disrupters and best-in-class operators in their related fields. Our experience and expertise in this sector position us to provide actionable advice and execute transactions that meet our clients' needs,” said Ivan Saval, Managing Director and Head of ROTH MKM's Agribusiness Investment Banking Group.

“Our focus on agtech and agribusiness is driven by the growing demand for sustainable and innovative solutions in the industry. Our group's expertise in these areas, combined with its global network of investors and buyers, positions us as a trusted advisor for entities considering an M&A or capital markets process,” Saval continued.


ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately held, employee owned organization and maintains offices throughout the U.S. For more information, please visit


Investor and Media Contact: ROTH MKM, Isabel Mattson-Pain, Director of Marketing,, 949-720-7117

Corteva Agriscience (CTVA), closed Tuesday's trading session at $60.93, up 1.0615%, on 2,120,100 volume with 00 trades. The average volume for the last 3 months is 25.222M and the stock's 52-week low/high is $50.03 /$68.43 .

Coinbase Global Inc. (COIN)

InvestorPlace, Schaeffer's, The Street, Prfmonline, Greenbackers, MarketClub Analysis, QualityStocks, MarketBeat, Kiplinger Today, OTCPicks, SmallCapVoice, Investopedia, Ceocast News, The Online Investor, CoolPennyStocks, HotOTC, Daily Trade Alert, Trades Of The Day, StockEgg, Penny Invest, Stock Stars, Early Bird, InsiderTrades, StocksEarning, Stock Rich, The Wealth Report, Top Pros' Top Picks, INO Market Report, The Stock Psycho, CNBC Breaking News, Top Gun, BestOtc, HotShotStocks, BullRally, StockHotTips, MadPennyStocks, FeedBlitz, Energy and Capital, Wealth Daily, Today's Financial News, StockRich, Zacks, PennyStockVille, Profit Confidential, Stockpalooza, PennyInvest, PennyTrader Publisher, Cabot Wealth, CRWEWallStreet, Atomic Trades, Green Chip Stocks, Early Investing, Blaque Capital Stocks, Dynamic Wealth Report, Eagle Financial Publications, BloomMoney, Standout Stocks, wyatt research newsletter, WiseAlerts, Wealth Whisperer, TipRanks, StockMister, StockEarnings, Stock Traders Chat, Penny Stock Rumble, Stock Analyzer, Louis Navellier, Smartmoneytrading, Round Up the Bulls, Pennybuster, AllPennyStocks, Penny Stock Finder, Momentum Traders, MicrocapVoice and Stock Fortune Teller reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

On April 6, 2023, Pakistani banks, through the PBA, signed a contract to implement an electronic know-your-customer (KYC) system based on blockchain that will function nationally. The signing event took place at the PBA’s office in Karachi, and several officials, including Waqas Mirza, CEO of the Avanza Group, and association chair Muhammad Aurangzeb, were present.

The Avanza Group, a company with expertise in artificial intelligence, modern banking applications, blockchain applications, and client-experience management solutions, will create the platform. Pakistani authorities want to narrow the gap between their country and other Asian countries such as Singapore, Indonesia, Hong Kong and Thailand, which have already made headway with their CBDC initiatives.

The new program, named Consonance, is intended to support Pakistan’s State Bank plan to improve the country’s infrastructure for controlling money laundering and countering terrorism financing. The system will enable banks to share customers’ personal information through a self-regulatory and decentralized network. The PBA states that this personal information exchange will only happen with the customers’ permission.

The platform will enable banks to evaluate new and existing clients using information from KYC checks carried out by other organizations. The change aims to reduce onboarding expenses while promoting financial inclusion by simplifying the account opening process for customers.

Blockchain allows for the permanent storage of financial transactions in an unchangeable format. By doing this, Pakistan’s current financial system might become more transparent.

Pakistan is currently experiencing a financial crisis. Internally, the nation has recently experienced a wave of terror attacks in various regions. Last week, the value of Pakistan’s fiat currency in relation to the U.S. dollar fell to an all-time low of PKR 285 due to the ongoing recession.

As a result, the nation has been refocusing on integrating blockchain and cryptocurrency into its financial system. Pakistan has made the decision to choose and authorize organizations that will issue electronic money to support online transactions.

Pakistan’s Finance Minister Asad Umar noted in December 2022 that the country’s commerce industries trade will be strengthened by dabbling in the burgeoning blockchain sector, while giving it a fair shot at competing in the fintech sector with other countries.

Pakistan created three subcommittees in January 2022 to investigate the cryptocurrency industry from all perspectives before the country makes a final decision regarding its position on its legalization.

According to a Chainalysis report, India and Pakistan, the second and third highest crypto adopters globally, have dropped to fourth and sixth place this year due to legal uncertainty.

This development in Pakistan is likely to be well received by companies such as Coinbase Global Inc. (NASDAQ: COIN) within the blockchain space because it shows that the industry is being taken seriously by major institutions around the world.

Coinbase Global Inc. (COIN), closed Tuesday's trading session at $70.19, up 6.1394%, on 25,348,828 volume with 00 trades. The average volume for the last 3 months is 159,693 and the stock's 52-week low/high is $31.55 /$162.44 .

Mind Medicine Inc. (MNMD)

InvestorPlace, QualityStocks, Schaeffer's, The Wealth Report, The Street, MarketBeat, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The next few decades will likely see psychedelic treatments go from relative obscurity to playing center stage in the psychiatric space. After decades of prohibition, psychedelics are now emerging as a potential alternative to traditional mental health therapies amid a surge in psychedelic research.

Numerous studies have revealed that hallucinogenic drugs can deliver significant mental health benefits when paired with talk therapy. Psychedelics may finally allow people to gain long-term relief from conditions such as post-traumatic stress disorder and depression, which often fail to respond to conventional treatments.

Although a lot of psychedelic research has occurred in Western countries such as the United States, Canada and Australia, other nations aren’t being left behind. In the Middle East, an Israeli startup plans to begin testing a new psychedelic spray to treat PTSD. Over the last two years, the Israeli Defense Ministry has identified that at least 5,000 Israelis suffer from post-traumatic stress disorder. The mental health disorder tends to affect women more than men, and is especially prevalent among soldiers who see active combat.

Existing therapies for PTSD aren’t always effective, and they don’t work for everyone, necessitating the development of more efficient PTSD treatments. The recent surge in psychedelic research has revealed that hallucinogenics have plenty of potential as therapies for PTSD, especially when paired with psychotherapy.

Madrigal Mental Care Facility chief of the advisory board, clinical psychologist and PTSD specialist Or Doek explains that there is no treatment for the underlying cause of PTSD and current treatments, such as antidepressants, are just meant to alleviate the symptoms.

Psychedelics are becoming increasingly popular as they offer patients a chance to deal with the underlying trauma and traumatic memories that cause disruptive mental health symptoms. Doek says that psychedelics help patients reframe traumatic memories from traumatic events to sad events and remove their negative power.

Madrigal Mental Care Facility founder David Gabbay developed technology that facilitates the delivery of hallucinogenics into the brain in minute doses. He explains that the technology encloses a psychedelic molecule in a nanobiodegradable capsule, which is then suspended in a nasal spray. The minuscule dose and the quick-delivery system cause immediate effects without the “psychedelic trip,” allowing patients to reframe prior traumatic events without experiencing hallucinogenic effects.

According to Gabbay, Madrigal Mental Care Facility is researching the effects of psilocybin, ketamine and ecstasy on the brain. The facility expects to begin human trials of its psychedelic nasal spray by 2024.

With all the investment being injected into psychedelic research and product development by companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), it may not be long before different formulations are approved for use via various administration methods tailored for different groups of patients.

Mind Medicine Inc. (MNMD), closed Tuesday's trading session at $3.01, up 0.333333%, on 159,693 volume with 00 trades. The average volume for the last 3 months is 64,194 and the stock's 52-week low/high is $2.12 /$19.95 .

The QualityStocks Company Corner

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Arizona Metals (TSX: AMC) (OTCQX: AZMCF) today announced that the first hole (KM-23-104) drilled at theWestern Target of the Kay Mine Project intersected 16 metres ofstringer to semi-massive sulphide mineralization, including visiblecopper sulphide (chalcopyrite) and zinc sulphide (sphalerite).According to the update, the VMS mineralization occurs within abroader interval of syn-mineral quartz-carbonate veiningaccompanied by sulphide minerals (pyrite, pyrrhotite, sphalerite,chalcopyrite, and arsenopyrite) and anomalous zinc and copperreadings from onsite portable XRF. The hole ended insulphide-bearing core but was stopped at 888 metres downhole due toseparated drill rods. Hole 104 was submitted for assay and resultsare pending. In addition, the company will continue testing thisnew zone of mineralization via a new branch hole, KM-23-104A.“Intersecting such a broad interval of VMS mineralization in ourvery first hole at the Western Target is extremely gratifying, andis another step towards confirming our thesis that mineralizationextends on our claims well beyond the footprint of the Kay MineDeposit,” said Marc Pais, CEO of Arizona Metals. “We have observedmineralization and alteration in this first hole that is similar towhat we see in proximity to massive sulphide mineralization at theKay Mine Deposit. With this first successful hole to guide ourtargeting, we are moving a second drill to the Western Target toaccelerate our testing of the new mineralized zone.” To view thefull press release, visit

The production of zinc around the globe is expected to experiencevolatility throughout the year as geopolitical factors impact thesupply chain. In April 2020, the coronavirus pandemic caused the demand for zinc to decline significantly, as zinc-intensive sectors such as transportation and constructionsignificantly slowed or shut down entirely. Zinc prices fell that month, with worries of a supply surplus and risk-offsentiment also reducing investor interest in the metal greatly.However, the supply surplus turned into a supply shortfall of 1 million tons in 2021 as demand began to increase. Thisrecovery proved to be short lived as global zinc production reduced by 1.2% to 12.8 million tons the following year. Declining output from major zinc producersAustralia and Peru was to blame for the reduced production in 2022,with the combined output from both nations reducing from 2.8million tons in 2021 to 2.7 million tons last year. In detail, zincproduction in Peru saw a 4.8 year-over-year reduction due to conflicts between locals and mining companies that paralyzed miningoperations in key places, such as Atacocha, Cuajone, andYauricocha. Additionally, a mudslide incident at the Yauricocha mine during the third quarter of 2022 preventedproduction for 20 full days. Canada also saw its zinc outputdecrease by 12.4%, Russian zinc production fell by 4.9% and zincproduction in China reduced by 0.3%. Zinc exploration companiessuch as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) are likely to look at these forecasts and adjust their strategicplans in order to benefit fully from the positive outlook for theglobal commodities market.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.


Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Vision Energy Corp. (OTCQX: AZMCF), closed Tuesday's trading session at $3.23, up 8.3893%, on 64,194 volume with 00 trades. The average volume for the last 3 months is 374,342 and the stock's 52-week low/high is $2.30 /$5.51 .

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies, Inc. (Nasdaq: FRGT, Fr8Tech or Company), a technology company developingsolutions to optimize and automate the supply chain process andproviding its Fr8App platform for B2B cross-border shipping in the USMCA region, Fr8now for LTL shipping services in Mexico and Fr8Fleet for dedicatedcapacity to enterprise companies in Mexico, previously announcedthat it received written notification on October 26, 2022, from TheNasdaq Stock Market LLC that it no longer complied with the minimumbid price requirement for continued listing on the Nasdaq CapitalMarket pursuant to the Nasdaq Listing Rule 5550(a)(2). The closingbid price for the Company's ordinary shares had fallen below $1.00per share for 30 consecutive business days and accordingly, theCompany no longer complied with the minimum bid price requirementfor continued listing on the Nasdaq Capital Market pursuant to theNasdaq Listing Rule 5550(a)(2). However the Nasdaq Listing Rulesalso provided the Company a compliance period of 180 calendar days(i.e. by April 24, 2023) in which to regain compliance. In order toregain compliance, the Company effected a 10: 1 reverse split ofits ordinary shares, which began trading on a split adjusted basison March 24, 2023. On April 11, 2023, the Company receivednotification from The Nasdaq Stock Market LLC that its Staff haddetermined that for the last 11 consecutive business days, fromMarch 24 through April 10, 2023, the closing bid price of theCompany’s ordinary shares had been at $1.00 per share or greater.Accordingly, the Company has regained compliance with Listing Rule5550(a)(2), and this matter is now closed.

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $2.16, up 2.3697%, on 375,705 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $5.51 /$.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (CSE: RFLX) (OTCQB: RFLXF).

Reflex Advanced Materials has begun the qualification process andboasts established relationships with more than 25 key NorthAmerican customers, putting it years ahead of the competition inthe lengthy graphite sales cycle

The company has executed two critical product development andmaterial research partnerships in an effort to diversify risk andimprove margins

Reflex Advanced Materials expects to begin fulfilling majorgraphite orders in 2024, with supply, processing partners anddemand already in place

The U.S. Department of Energy is in the process of awarding $2.8billion to expand domestic manufacturing of batteries for electricvehicles, and the company has identified its Ruby Graphite Projectas a ‘prime candidate’ for U.S.-sponsored initiatives

A rise in anode demand is expected to fuel a shortage of 8 milliontonnes by 2040, with World Bank Group projecting 494% growth ingraphite demand by 2050

Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developingeconomic properties in the strategic metals and advanced materialsspace. The company aims to improve domestic specialty mineralinfrastructure efficiencies to meet surging national demand fromNorth American manufacturers, effectively positioning itself as oneof the only North American suppliers of high purity naturalgraphite for hi-tech applications.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Tuesday's trading session at $0.3015, up 0%, on volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25 /$0.765 .

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Last Thursday, Montana’s Senate Committee for Economic and Labor Affairs approved SB 546 on a 6-to-4 vote count, giving it a pass for further Senatediscussion. The bill, introduced by Senator Keith Regier, aimed to significantly reduce the potency of the medicinalcannabis plant and products in Montana by outlawing adult-use marijuana businesses, increasing the taxation on medical cannabis from 4% to 20%, andplacing strict restrictions on the amount that can be legallypossessed. It also aimed to reduce the number of marijuana plantsgrown for personal use from two to one. Advocates for medicinalmarijuana challenged the law, claiming it would prevent patientswho depend on it for treating pain and other conditions fromaccessing it. Numerous individuals would not have been able toafford medical marijuana because of the anticipated tax rise.Three GOP committee members — Committee Chair Jason Small, Senate President Jason Ellsworthand Senator Sales Walt — joined forces with all three Democratic members to reject the measure. Supporters of medical cannabis who havepushed for access to relatively affordable medical marijuanacelebrated this ruling as a victory. The failure of this measureleaves patients with marijuana cards still able to grow their ownmedicinal cannabis plants using some modern equipment, such as themini-gardens sold by Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.3, up 0%, on 218 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.073 /$1.25 .

Recent News

Data443 Risk Mitigation Inc. (OTC: ATDS)

The QualityStocks Daily Newsletter would like to spotlight Data443 Risk Mitigation Inc. (OTC: ATDS).

Data443 (OTC: ATDS), a data security and privacy software company for “All Things DataSecurity,” today announced an additional contract win from one ofits largest fintech clients. The client, a leading globalorganization providing merchant, banking and capital marketsolutions marketplaces, processes over 75 billion transactionsamounting to more than $9 trillion annually. Data 443 has been atrusted partner for the client’s enterprise file transfer servicerequirements for more than 15 years. Data443’s Data PlacementManager processes thousands of sensitive data files per hour forthousands of partners around the globe, and the company’s platformcontinues significant focus on secure data discovery,identification, governance and distribution. According to aGartner(R) report*, “Managed file transfer (‘MFT’) is a majormarket segment, with rapid growth of managed file transferplatform-as-a-service (‘MFTPaaS’) in the segment.” “The analysisfrom the referenced Gartner report matches our experience – movinghighly sensitive data in a completely secure, audited andoperationalized capability is a major business driver for ourclients,” said Jason Remillard, CEO and founder of Data443. “Moreorganizations outside of fintech, such as insurance, ratingagencies, and other large and small banks, are now needing thesecapabilities. There are two major use cases that largely drivecustomers’ accelerated move to MFTPaaS: the growing need for rapidand managed data movement capabilities leveraging cloud-firstarchitectures and constraints around staffing for operators anddata engineers.” To view the full press release, visit

Data443 Risk Mitigation Inc. (OTC: ATDS) is a data security and privacy software company for ALL THINGS DATA SECURITY™. The company is committed to organizing the world’s information by identifying and protecting all sensitive data regardless of location, platform or format.

Data443 provides software and services to enable secure data across devices and databases – at rest and in transit – locally, on a network, or in the cloud. With over 10,000 customers in more than 100 countries, Data443 provides a modern approach to data governance and security. The company’s framework helps customers prioritize risk, identify security gaps, and implement effective data protection and privacy management strategies.

Data443 derives revenue primarily from contracts for subscriptions to access its SaaS platforms, and ancillary services provided in connection with its subscription services. In today’s ever-changing environment with unique and complex requirements for data privacy, governance and hybrid workforces, every organization needs to know where all their data is, who has access to it and how sensitive it is. Data443 provides the tools needed to give companies control over their data processing activities, with capabilities for identifying, reporting and migrating or deleting sensitive data.

The company is headquartered in Research Triangle Park, North Carolina.


Focused on data security with a privacy-forward methodology, the Data443 product suite delivers solutions designed to securely manage data and data privacy needs on-premises, in the cloud and in hybrid environments. Offerings include:

  • Data Identification Manager reduces risk by shining a light on dark data across cloud, on-premises and hybrid environments. From a centralized dashboard, Data Identification Manager provides the ability to automatically inventory all data repositories, classify and tag all data, and enable global search and discovery – all through an agentless deployment.
  • Data Placement Manager quickly and securely transfers sensitive data over any public or private network. Available as an HP Nonstop server-based application and for Windows, Linux or any public cloud provider, Data Placement Manager enables the scheduling, routing, formatting and transfer of business-critical data.
  • Data Archive Manager is an “all information, anywhere” archiving solution designed to handle and manage all types of privacy requests across cloud, on-premises and hybrid environments. With over 15 years operational history and hundreds of clients managing millions of mailboxes, the platform is purpose-built for information archiving, retention and privacy request management.
  • Data Hound™ is a data discovery, classification and capture toolset that enables organizations to perform quick scans, detailed reporting and subsequent data actions based on policy.
  • Ransomware Recovery Manager is the only industry solution that actively recovers the device, operating system and data with a simple reboot. Using patented, proven technology, the product produces 100% effectiveness for the whole device and datasets.
  • Access Control Manager provides user ID and passwordless access to quickly enable trust across an organization’s entire ecosystem. Its unique architecture allows it to leverage multiple distributed authoritative sources to understand and resolve a typical access request – with the ability to enable or deny the action on the fly.
  • Global Privacy Manager provides organizations one comprehensive view, for all privacy requirements, across all enterprise data, all at once. This unmatched visibility into an organization’s data assets ensures that all private and sensitive data can be identified and protected and that enterprises can obey all relevant privacy laws in any jurisdiction.
  • Sensitive Content Manager is a security-centric collaboration service designed to give organizations the tools needed for successful content sharing, collaboration and safe distribution with full enterprise management in mind. With a continuous sync feature, encrypted data is automatically downloaded and updated in real time – regardless of location – ensuring that users have the most accurate data available.

Market Outlook

A report from Allied Market Research estimates that the global data security market was worth about $19 billion in 2021 and is projected to reach a value of $54.23 billion by 2027. That represents a CAGR of more than 18% for the forecast period, making data security one of the hottest areas within IT.

Separately, Fortune Business Insights estimates the global data privacy software market is valued at $2.36 billion in 2022 and projects it will grow to $25.85 billion by 2029. That represents a CAGR of 40.8% over the forecast period.

Management Team

Jason Remillard is President, CEO and Founder of Data443. He is responsible for overseeing global expansion, management, execution and corporate development. With over 25 years in global enterprise and B2C software sales and marketing, he brings deep leadership and technical experience, having spent previous time at Fortune 500 companies such as Deutsche Bank, TD Bank, IBM & Merrill Lynch.

Greg McCraw is CFO at Data443. He has over 25 years of experience helping businesses strengthen their accounting and finance operations. He previously served as Vice President of Finance for a dental services organization active in acquisitions, and, prior to that, he was managing director of a boutique accounting and finance consulting firm advising Fortune 500 clients in pharmaceutical, financial services, and private equity sectors on how to execute on regulatory and compliance solutions.

Bennett Pursell is Data443’s Chief Technology Officer. He has over 20 years of experience in IT architecture, security governance and systems integration. Prior to his role at Data443, he served as Head of Technology Architecture at Moody’s Investor Services and was Vice President and Technical Architect of Cloud Computing at Deutsche Bank, along with a host of technical and project management roles dating back to 2006, after starting his career as a web developer with a few startups and running research labs.

Kirill Kashigin is Chief Software Architect at Data443. He leads the development and quality teams, and serves as technical adviser and subject matter expert, bringing vast technical knowledge on privacy management and data security. Formerly the CTO of FileFacets, he has nearly 20 years in development of high-performance systems and deployment.

Data443 Risk Mitigation Inc. (OTC: ATDS), closed Tuesday's trading session at $0.065, up 0%, on 104 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.025 /$6.99 .

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar’s SmartGreen(TM) whole-home renewable energy systempotentially reduces dependence on fossil fuels while lowering oreven completely eliminating utility bills

The SmartGreen(TM) system includes photovoltaic solar panels,geothermal ground loops, integrated air ducts and floor loops,CERV(R) air filtration, upgrades to lighting systems, windows,insulation

The SmartGreen(TM) system can be integrated into new constructionprojects or existing buildings

GeoSolar plans to market SmartGreen(TM) to over 120 million homesacross the U.S. with various financing options, tax deductions,utility incentives

The Intergovernmental Panel on Climate Change (“IPCC”) has statedthat there is over a 95% probability that the observed warming ofthe Earth’s surface since the mid-20th century is being caused byhuman activities ( Global policies aimed at reducing carbon emissions includecarbon pricing initiatives that incentivize reduced carbonfootprints, energy efficiency standards, renewable energyincentives, and international agreements.GeoSolar Technologies (“GST”) is committed to enabling a carbon-free future with theirSmartGreen(TM) Home system — a whole home renewable energy systemthat helps homeowners reduce or eliminate carbon use while savingmoney and achieving energy independence.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Fintech Ecosystem Development Corp. (the "Company") (NASDAQ:FEXD),announced today that it intends to adjourn, without conducting anybusiness, the Company's special meeting of stockholders (the"Special Meeting") originally scheduled to be held on Wednesday,April 12, 2023, and to reconvene the Special Meeting at 10:00 a.m.,Eastern time, on Thursday, April 20, 2023. In connection with theadjournment of the Special Meeting, the Company is extending thedeadline for holders of its shares of Class A common stock toexercise their right to redeem their shares for their pro rataportion of the funds available in the Company's trust account, orto withdraw any previously delivered demand for redemption, to 5:00p.m., Eastern time, on April 18, 2023 (two business days before theadjourned Special Meeting).

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Tuesday's trading session at $10.5899, up -0.095283%, on 5,519 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $9.96 /$11.00 .

Recent News

Progressive Care Inc. (OTCQB: RXMD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: RXMD).

Accurate and timely information plays a crucial role in maintainingpublic health. As the recent coronavirus pandemic showed, securing the right information as early as possible canallow for the creation of preventative and mitigation strategies.Even though the worst of the pandemic is now behind us, somelessons we learned, such as the value of transmitting electronic health records (EHR) to public health agencies, will still be significant movingforward. NYU Grossman School of Medicine’s Lorna Thorpe, PhD, andBrian Dixon, PhD, MPA, from Indiana University Richard M. FairbanksSchool of Public Health and the Regenstrief Institute, will talkabout the significance of EHR at the upcoming HIMMS Global Health Conference & Exhibition.While the primary reason for entering patient information intoelectronic records is to track their treatment and health, thisinformation has greater significance. Dixon says that electronic health records can also be used for public healthpurposes, especially tracking new cases of conditions such ashypertension and diabetes. This data can also help to calculate therates at which hypertension and diabetes are affecting thepopulation, he noted. Health service organizations such as Progressive Care Inc. (OTCQB: RXMD) have a significant role to play to enable health data to helppolicymakers have a clearer picture of how diseases break out andspread in different sections of the global population.

Progressive Care Inc. (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (TPA), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (MTM), long-term care facility-targeted prescription medications, and health practice risk management.

The company collaborates with various healthcare organizations such as managed care organizations (MCOs), management services organizations (MSOs), accountable care organizations (ACOs), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise.

With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions.


Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients.

PharmcoRx Pharmacy

PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program.


ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Market Opportunity

According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period.

The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business.

Management Team

Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY).

Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge.

FingerMotion Inc. (RXMD), closed Tuesday's trading session at $2.56, up -14.6667%, on 8,752 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $2.00 /$10.40 .

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals recently announced it had enrolled the firstpatient in Switzerland as part of its ongoing potentially pivotalglobal GBM trial

The adaptive, multicenter, open-label, randomized controlled trialis evaluating Berubicin for the treatment of recurrent GBM, themost common primary brain cancer, compared to Lomustine, thecurrent standard of care

The enrollment moves the company closer to its goal of undertakingan interim analysis expected in the third quarter of 2023

So far, CNS Pharmaceuticals has opened over 40 of 59 plannedclinical trial sites selected across Switzerland, Spain, France,Italy, and the U.S.

As an aside, the company announced it does not hold any deposits orinvestments at the now-collapsed Silicon Valley Bank (“SVB”)

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in thedevelopment of novel treatments, recently reported the enrolment ofthe first patient in Switzerland as a participant in its ongoingpotentially pivotal global trial evaluating Berubicin for thetreatment of recurrent glioblastoma multiforme (“GBM”) (

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.7002, up -6.5403%, on 447,498 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105 /$13.20 .

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software, and services,and the only quantum computing company building commercialannealing quantum computing systems and developing gate-modelquantum computing systems, will soon be releasing its financialresults for the fourth quarter and fiscal year 2022, for the periodending Dec. 31, 2022. The company noted it plans to release thereport before market opens on April 14, 2023. In addition, thecompany has also scheduled an earnings call for the same day, whichis slated to begin at 8 a.m. ET. Those interested in accessing thecall can dial 1-877-407-3982 (domestic) or 201-493-6780(international), and use the conference ID code 13738032. D-WaveCEO Alan Baratz and CFO John Markovich will be hosting the liveevent, which will also be available via webcast on the company’sinvestor relations website. To view the webcast, visit To view the full press release, visit

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $0.639, up -24.8324%, on 4,479,832 volume with 00 trades. The average volume for the last 3 months is 4.443M and the stock's 52-week low/high is $0.491 /$13.23 .

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

Officials in Germany intend to move forward with a toned-down version of cannabis legalization after abandoning — at least temporarily — a more comprehensiveproposal that would have brought about legal cannabis salesthroughout the nation. Karl Lauterbach, the nation’s healthminister, had promised to introduce new marijuana regulations bythe end of March this year. The new model, which consists of twoparts, was first reported by Zeit and aims to legalize cannabis countrywide without breaking EUregulations. The model will, for four years, permit restrictedcannabis sales in some areas, much like a pilot program. In doingso, officials would be able to observe how reforms were beingimplemented in both urban centers and more rural areas. The programcan then be expanded to other regions of the nation if it is deemedsuccessful. Lauterbach’s plan would also permit Germans tocultivate marijuana for personal use. While the latter part of theplan would require review by the EU Commission, the former wouldnot, according to reports. As more countries around the world takesteps to end the prohibition of marijuana, many companies such as IGC Pharma Inc. (NYSE American: IGC) are going a step further to develop medicines from compoundsextracted from this plant, and these compounds are expected to gainthe approval of regulators once the the clinical developmentprocess has been successfully completed.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Tuesday's trading session at $0.3399, up 0%, on 56,453 volume with 00 trades. The average volume for the last 3 months is 51,389 and the stock's 52-week low/high is $0.2785 /$0.8933 .

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.


Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Tuesday's trading session at $0.0001, up 0%, on 5,133,425 volume with 00 trades. The average volume for the last 3 months is 5.133M and the stock's 52-week low/high is $0.000001 /$0.0006 .

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.